FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2238408350> ?p ?o ?g. }

• W2238408350 endingPage "iv83" @default.
• W2238408350 startingPage "iv83" @default.
• W2238408350 abstract "Introduction: The Köhne risk classification was established in mCRC patients (pts) treated with 5-fluorouracil-based chemotherapy. (Ann Oncol 2002;12:308-317). Afterwards the GERCOR group developed a prognostic model for pts treated with an oxaliplatin-based or irinotecan-based 1st-line chemotherapy. (The Oncologist 2011;16:1228-1238). Bevacizumab (Bev) in combination with FOLFOX/FOLFIRI has shown a survival benefit in the 1st-line therapy and is considered a standard of treatment in mCRC; however, validated prognostic models are not available in these pts treated with antiangiogenics.Methods: Retrospective review of FOLFOX/FOLFIRI-Bev treated pts (2006-2013). Progression-free survival (PFS) and OS were assessed. Univariate and multivariate analysis of prognostic factors for OS was performed. To study the correlation between the Köhne and GERCOR prognostic models, each model's predicted survival was plotted and a Pearson's correlation coefficient was used to analyze the similarity between these two prognostic indexes.Results: 124 pts found. Baseline characteristics in Table 1. With a median follow-up of 65 months (mts) (range 22-112), median (m) PFS and OS was 10.9 (CI95% 9,1-12,8) and 26.8 mts (CI95% 19,4-34,4), respectively. The 1-, 2-, and 5-year OS rate was of 84%, 59% and 14%. Univariate analysis: Performance status (PS) = 2, anemia, hypoalbuminemia, high CA 19.9 baseline level, elevated serum lactate dehydrogenase (LDH) at baseline, > 1 metastatic site, were all significant poor prognostic factors. In the multivariate study, only PS, number of metastatic sites, and serum LDH retained their significant prognostic value. By applying the Köhne model, mOS was 35.2 mts (CI95% 28-42.3) in the low-risk group, 24.1 mts (CI95% 18.2-30.1) in the intermediate-risk group and 3.6 mts (CI95% 0.1-7.9) in the high-risk group. (p-value < 0.0001). According to the GERCOR model, mOS was 38.8 mts (CI95% 25.1-52.4) in the low-risk group, 26.1 mts (CI95% 15.7-36.5) in the intermediate-risk and 17.1 mts (CI95% 14.7-19.5) in the high-risk group, respectively (p-value< 0.0001). A moderate positive relationship was confirmed between them, with a Pearson coefficient of 0,413 that was statistically significant (p-value < 0,0001).Conclusion: PS, serum LDH baseline value, number of metastatic sites were the main prognostic factors in our pts treated with 1st-line FOLFOX/FOLFIRI-Bev. The GERCOR prognostic appears to have advantages over the Köhne model for risk-stratification of patients outside clinical trials, especially in the selection of higher-risk patients.Table: P-281 Introduction: The Köhne risk classification was established in mCRC patients (pts) treated with 5-fluorouracil-based chemotherapy. (Ann Oncol 2002;12:308-317). Afterwards the GERCOR group developed a prognostic model for pts treated with an oxaliplatin-based or irinotecan-based 1st-line chemotherapy. (The Oncologist 2011;16:1228-1238). Bevacizumab (Bev) in combination with FOLFOX/FOLFIRI has shown a survival benefit in the 1st-line therapy and is considered a standard of treatment in mCRC; however, validated prognostic models are not available in these pts treated with antiangiogenics. Methods: Retrospective review of FOLFOX/FOLFIRI-Bev treated pts (2006-2013). Progression-free survival (PFS) and OS were assessed. Univariate and multivariate analysis of prognostic factors for OS was performed. To study the correlation between the Köhne and GERCOR prognostic models, each model's predicted survival was plotted and a Pearson's correlation coefficient was used to analyze the similarity between these two prognostic indexes. Results: 124 pts found. Baseline characteristics in Table 1. With a median follow-up of 65 months (mts) (range 22-112), median (m) PFS and OS was 10.9 (CI95% 9,1-12,8) and 26.8 mts (CI95% 19,4-34,4), respectively. The 1-, 2-, and 5-year OS rate was of 84%, 59% and 14%. Univariate analysis: Performance status (PS) = 2, anemia, hypoalbuminemia, high CA 19.9 baseline level, elevated serum lactate dehydrogenase (LDH) at baseline, > 1 metastatic site, were all significant poor prognostic factors. In the multivariate study, only PS, number of metastatic sites, and serum LDH retained their significant prognostic value. By applying the Köhne model, mOS was 35.2 mts (CI95% 28-42.3) in the low-risk group, 24.1 mts (CI95% 18.2-30.1) in the intermediate-risk group and 3.6 mts (CI95% 0.1-7.9) in the high-risk group. (p-value < 0.0001). According to the GERCOR model, mOS was 38.8 mts (CI95% 25.1-52.4) in the low-risk group, 26.1 mts (CI95% 15.7-36.5) in the intermediate-risk and 17.1 mts (CI95% 14.7-19.5) in the high-risk group, respectively (p-value< 0.0001). A moderate positive relationship was confirmed between them, with a Pearson coefficient of 0,413 that was statistically significant (p-value < 0,0001). Conclusion: PS, serum LDH baseline value, number of metastatic sites were the main prognostic factors in our pts treated with 1st-line FOLFOX/FOLFIRI-Bev. The GERCOR prognostic appears to have advantages over the Köhne model for risk-stratification of patients outside clinical trials, especially in the selection of higher-risk patients. Table: P-281" @default.
• W2238408350 created "2016-06-24" @default.
• W2238408350 creator A5003774647 @default.
• W2238408350 creator A5011161678 @default.
• W2238408350 creator A5019310721 @default.
• W2238408350 creator A5028113456 @default.
• W2238408350 creator A5046073176 @default.
• W2238408350 creator A5047809217 @default.
• W2238408350 creator A5048388712 @default.
• W2238408350 creator A5053968478 @default.
• W2238408350 creator A5060170484 @default.
• W2238408350 creator A5066901239 @default.
• W2238408350 creator A5073012839 @default.
• W2238408350 creator A5073753205 @default.
• W2238408350 creator A5090318520 @default.
• W2238408350 creator A5090612800 @default.
• W2238408350 date "2015-06-01" @default.
• W2238408350 modified "2023-10-16" @default.
• W2238408350 title "P-281 The GERCOR and Köhne prognostic models in metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based first-line therapy: comparison and validation of both models in a real-life setting" @default.
• W2238408350 doi "https://doi.org/10.1093/annonc/mdv233.278" @default.
• W2238408350 hasPublicationYear "2015" @default.
• W2238408350 type Work @default.
• W2238408350 sameAs 2238408350 @default.
• W2238408350 citedByCount "0" @default.
• W2238408350 crossrefType "journal-article" @default.
• W2238408350 hasAuthorship W2238408350A5003774647 @default.
• W2238408350 hasAuthorship W2238408350A5011161678 @default.
• W2238408350 hasAuthorship W2238408350A5019310721 @default.
• W2238408350 hasAuthorship W2238408350A5028113456 @default.
• W2238408350 hasAuthorship W2238408350A5046073176 @default.
• W2238408350 hasAuthorship W2238408350A5047809217 @default.
• W2238408350 hasAuthorship W2238408350A5048388712 @default.
• W2238408350 hasAuthorship W2238408350A5053968478 @default.
• W2238408350 hasAuthorship W2238408350A5060170484 @default.
• W2238408350 hasAuthorship W2238408350A5066901239 @default.
• W2238408350 hasAuthorship W2238408350A5073012839 @default.
• W2238408350 hasAuthorship W2238408350A5073753205 @default.
• W2238408350 hasAuthorship W2238408350A5090318520 @default.
• W2238408350 hasAuthorship W2238408350A5090612800 @default.
• W2238408350 hasBestOaLocation W22384083501 @default.
• W2238408350 hasConcept C121608353 @default.
• W2238408350 hasConcept C126322002 @default.
• W2238408350 hasConcept C143998085 @default.
• W2238408350 hasConcept C144301174 @default.
• W2238408350 hasConcept C2776694085 @default.
• W2238408350 hasConcept C2776705615 @default.
• W2238408350 hasConcept C2776907518 @default.
• W2238408350 hasConcept C2777802072 @default.
• W2238408350 hasConcept C2778260052 @default.
• W2238408350 hasConcept C2780259306 @default.
• W2238408350 hasConcept C2780739268 @default.
• W2238408350 hasConcept C2780962732 @default.
• W2238408350 hasConcept C38180746 @default.
• W2238408350 hasConcept C526805850 @default.
• W2238408350 hasConcept C71924100 @default.
• W2238408350 hasConceptScore W2238408350C121608353 @default.
• W2238408350 hasConceptScore W2238408350C126322002 @default.
• W2238408350 hasConceptScore W2238408350C143998085 @default.
• W2238408350 hasConceptScore W2238408350C144301174 @default.
• W2238408350 hasConceptScore W2238408350C2776694085 @default.
• W2238408350 hasConceptScore W2238408350C2776705615 @default.
• W2238408350 hasConceptScore W2238408350C2776907518 @default.
• W2238408350 hasConceptScore W2238408350C2777802072 @default.
• W2238408350 hasConceptScore W2238408350C2778260052 @default.
• W2238408350 hasConceptScore W2238408350C2780259306 @default.
• W2238408350 hasConceptScore W2238408350C2780739268 @default.
• W2238408350 hasConceptScore W2238408350C2780962732 @default.
• W2238408350 hasConceptScore W2238408350C38180746 @default.
• W2238408350 hasConceptScore W2238408350C526805850 @default.
• W2238408350 hasConceptScore W2238408350C71924100 @default.
• W2238408350 hasLocation W22384083501 @default.
• W2238408350 hasOpenAccess W2238408350 @default.
• W2238408350 hasPrimaryLocation W22384083501 @default.
• W2238408350 hasRelatedWork W1999397682 @default.
• W2238408350 hasRelatedWork W2037672098 @default.
• W2238408350 hasRelatedWork W2077546410 @default.
• W2238408350 hasRelatedWork W2417717847 @default.
• W2238408350 hasRelatedWork W2516316080 @default.
• W2238408350 hasRelatedWork W2591743724 @default.
• W2238408350 hasRelatedWork W2892376819 @default.
• W2238408350 hasRelatedWork W2908369437 @default.
• W2238408350 hasRelatedWork W3041018076 @default.
• W2238408350 hasRelatedWork W4361957679 @default.
• W2238408350 hasVolume "26" @default.
• W2238408350 isParatext "false" @default.
• W2238408350 isRetracted "false" @default.
• W2238408350 magId "2238408350" @default.
• W2238408350 workType "article" @default.